Mural Oncology to Participate in Major Investor Conferences
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its involvement in two important investor conferences. At these events, the management team will engage with stakeholders through presentations and one-on-one meetings. Key executives will share insights into the company's innovative, investigational engineered cytokine therapies, which aim to meet critical medical needs in the oncology sector.
Upcoming Conferences
At the Morgan Stanley 22nd Annual Global Healthcare Conference, Caroline Loew, Ph.D., the CEO, will join a fireside chat with Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer. This engaging discussion is set for Friday, September 6, at 1:50 p.m. ET.
H.C. Wainwright 26th Annual Global Investment Conference
Mural Oncology will also take part in the H.C. Wainwright 26th Annual Global Investment Conference. During this event, CEO Caroline Loew, Ph.D., will present the company’s progress and future plans. This presentation is scheduled for Wednesday, September 11, at 9:30 a.m. ET.
About Mural Oncology
Mural Oncology is leading the way in developing groundbreaking immunotherapies through its advanced protein engineering platform. The company combines deep expertise in cytokine biology and immune cell modulation to create treatments that provide significant clinical benefits for cancer patients. Their leading candidate, nemvaleukin, is currently advancing through potentially registrational trials targeting mucosal melanoma and platinum-resistant ovarian cancer.
Mission and Vision
Mural Oncology's mission is clear: to enhance the potential and accessibility of cytokine-based immunotherapies, ultimately improving the quality of life for cancer patients. Their dedication to innovative research and development establishes Mural Oncology as a frontrunner in the battle against cancer.
Corporate Information
The registered office of Mural Oncology is situated in Dublin, Ireland, while its primary facilities are located in Waltham, Massachusetts. The company's ongoing research efforts in oncology underscore their commitment to patient care and the development of innovative treatment options.
Contact Information
For further inquiries, please reach out to:
Katie Sullivan
Email: katie.sullivan@muraloncology.com
Frequently Asked Questions
What is the focus of Mural Oncology?
Mural Oncology is dedicated to developing novel immuno-oncology therapies designed to treat various types of cancer using engineered cytokines.
What are the dates of the upcoming conferences?
The Morgan Stanley Annual Global Healthcare Conference will take place on September 6, and the H.C. Wainwright Annual Global Investment Conference is scheduled for September 11.
Who will be presenting on behalf of Mural Oncology?
Presentations will be delivered by Caroline Loew, Ph.D., CEO, along with other key members of the management team.
What is nemvaleukin?
Nemvaleukin is Mural Oncology's lead candidate, currently undergoing clinical trials to assess its effectiveness against mucosal melanoma and platinum-resistant ovarian cancer.
How can I learn more about Mural Oncology?
For additional information, visit Mural Oncology’s website or follow the company on their LinkedIn and X profiles.